Sancilio & Company Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sancilio & Company Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10545
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sancilio & Company Inc (SCI), a subsidiary of Sancilio Pharmaceuticals Company Inc is a drug development company that develops, manufactures and markets over the counter and generic prescription products. The company provides products such as omega-3, ludent sodium fluoride chewable tablets and multivitamin chewable tablets with fluoride and sodium fluoride drops. It offers services such as formulation development, analytical chemistry and packaging. SCI provides medicines that prevent common health problems and eliminate deficiencies. It develops Advanced Lipid Technologies using lipophilic compounds such as fatty acids, hormones, several vitamins, and many active pharmaceutical ingredients. SCI is headquartered in Riviera Beach, Florida, the US.

Sancilio & Company Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sancilio & Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sancilio & Company Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sancilio Pharma Raises USD5 Million in Venture Financing 11
Sancilio & Company Raises USD20 Million in Venture Financing 12
Sancilio & Company Raises US$2 Million In Venture Financing 13
Equity Offering 14
Sancilio Pharma Withdraws IPO 14
Sancilio Pharma Raises USD20 Million in Private Placement of Series C Preferred Stock 15
Sancilio & Company Inc – Key Competitors 16
Sancilio & Company Inc – Key Employees 17
Sancilio & Company Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product Approvals 19
Sep 19, 2017: Sancilio Pharmaceuticals Company, Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for Altemia a Treatment of Sickle Cell Disease (SCD) in Children 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sancilio & Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sancilio & Company Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sancilio & Company Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sancilio Pharma Raises USD5 Million in Venture Financing 11
Sancilio & Company Raises USD20 Million in Venture Financing 12
Sancilio & Company Raises US$2 Million In Venture Financing 13
Sancilio Pharma Withdraws IPO 14
Sancilio Pharma Raises USD20 Million in Private Placement of Series C Preferred Stock 15
Sancilio & Company Inc, Key Competitors 16
Sancilio & Company Inc, Key Employees 17

List of Figures
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sancilio & Company Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sancilio & Company Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gazprom Neft (SIBN):石油・ガス:M&Aディール及び事業提携情報
    Summary Gazprom Neft, a subsidiary of Gazprom, is an integrated oil and gas company. It explores for, develops, and produces crude oil and natural gas. The company operates in Khanty-Mansi and Yamalo-Nenets Autonomous Districts, and Tomsk, Omsk and Orenburg regions in Russia; and also has production …
  • Resona Holdings, Inc.:企業の戦略・SWOT・財務情報
    Resona Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Resona Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Austrian Post:企業のM&A・事業提携・投資動向
    Austrian Post - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Austrian Post Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Banque Degroof Petercam Private Banking:企業の戦略・SWOT・財務情報
    Banque Degroof Petercam Private Banking - Strategy, SWOT and Corporate Finance Report Summary Banque Degroof Petercam Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Pine Cliff Energy Ltd (PNE):石油・ガス:M&Aディール及び事業提携情報
    Summary Pine Cliff Energy Ltd (Pine Cliff) is an oil and gas company that offers exploration, production, and development of natural gas, crude oil, and natural gas liquids. The company operates through its core areas such as Edson Assets, Central Assets, and Southern Assets. It acquired Hatton prop …
  • Link Health Group:製薬・医療:M&Aディール及び事業提携情報
    Summary Link Health Group (Link Health) is a pharmaceutical company focused on the discovery and development of novel drug candidates for the treatment of cancer and other diseases. Its pipeline product portfolio includes LH011, an oral small molecule serine protease inhibitor for treating pancreati …
  • Ingram Micro Inc.:企業の戦略的SWOT分析
    Ingram Micro Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Pattern Energy Group Inc (PEGI):企業の財務・戦略的SWOT分析
    Pattern Energy Group Inc (PEGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • ZIOPHARM Oncology Inc (ZIOP):企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • Altium Ltd:企業の戦略・SWOT・財務情報
    Altium Ltd - Strategy, SWOT and Corporate Finance Report Summary Altium Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • The Bank of Nagoya, Ltd.:企業の戦略・SWOT・財務情報
    The Bank of Nagoya, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Bank of Nagoya, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Aminex PLC (AEX):企業の財務・戦略的SWOT分析
    Summary Aminex PLC (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration, and Ruvuma e …
  • Panda Green Energy Group Ltd:企業のM&A・事業提携・投資動向
    Panda Green Energy Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Panda Green Energy Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Scholastic Corporation:企業の戦略・SWOT・財務分析
    Scholastic Corporation - Strategy, SWOT and Corporate Finance Report Summary Scholastic Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Lexicon Pharmaceuticals Inc (LXRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program …
  • Saniona AB (SANION):製薬・医療:M&Aディール及び事業提携情報
    Summary Saniona AB (Saniona), formerly Aniona is a research and development company that develops drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company’s pipeline products include tesofensine, a triple monoamine reuptake inhibitor, which …
  • Selecta Biosciences Inc (SELB):製薬・医療:M&Aディール及び事業提携情報
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (S …
  • MediaCorp Pte Ltd:企業の戦略的SWOT分析
    MediaCorp Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Capricor Therapeutics Inc (CAPR):企業の財務・戦略的SWOT分析
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Alimentation Couche-Tard Inc.:企業の戦略・SWOT・財務情報
    Alimentation Couche-Tard Inc. - Strategy, SWOT and Corporate Finance Report Summary Alimentation Couche-Tard Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆